Integer (US:ITGR) Businesswire·2025-12-22 17:55Core Viewpoint - Integer Holdings Corporation has faced significant challenges, leading to a reduction in its sales guidance for 2025 and a negative outlook for 2026, which has resulted in a substantial decline in its stock price [2][3]. Financial Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which is below prior expectations [2]. - The company anticipates net sales growth of –2% to 2% and organic sales growth of 0% to 4% for 2026 [2]. Product Performance - Management indicated that sales of three new products, including two electrophysiology devices, are expected to decline in 2026 due to slower market adoption than forecasted [2]. - The Cardio & Vascular sales growth is expected to decelerate, primarily due to declines in the electrophysiology products, with this impact continuing into 2026 [2]. Stock Market Reaction - Following the announcement of the reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [3]. Legal Proceedings - A class action lawsuit has been filed alleging that Integer made materially false and misleading statements regarding its business and operations during the class period from July 25, 2024, to October 22, 2025 [4]. - The lawsuit claims that Integer overstated its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as long-term growth drivers [4].